Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terlipressin vs Midodrine for PICD Prevention in Cirrhosis
NCT03144713Completed
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- May 2017
- Primary completion
- Apr 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of terlipressin and midodrine in Paracentesis-Induced Circulatory Dysfunction (PICD) (3 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Incidence of Paracentesis Induced Circulatory Dysfunction at Day 6. Started May 2017; status: completed.
02
Drugs
terlipressinmidodrine
03
Conditions
Paracentesis-Induced Circulatory Dysfunction (PICD)
Beyond the preview
Go deeper on NCT03144713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03144713.